Hims & Hers Health stock falls around 3.5% as sustained selling pressure and negative technical momentum dominate trading

Traders Union
All News
Stocks
Hims & hers slides 3.45% today

Highlights

Shares of Hims & Hers Health trade below key short and long-term moving averages, indicating persistent selling pressure.
Momentum indicators confirm a negative bias, with most signaling a strong sell or neutral stance and no clear oversold conditions.
The stock is forecast to consolidate between $25.4 and $29.46 over five days, with an 80% probability of a downward move.

Anton Kharitonov, expert at Traders Union, views the current setup for Hims & Hers Health as technically and fundamentally weak. He notes the stock trades below all major moving averages and shows no signs of sustaining intraday gains. Technical momentum is persistently negative, and sentiment is fragile, as buyers fail to hold recent advances. The absence of supportive news only adds to the current vulnerability. Kharitonov warns, "Without a catalyst or technical reversal, further declines look likely and I would remain extremely cautious on this name."

Viktoras Karapetjanc, expert at Traders Union, sees opportunity for investors willing to look past short-term volatility. He highlights that the long-term bullish structure, reflected in 50-day versus 200-day alignment, remains intact despite current selling pressure. No negative news has emerged to fundamentally undermine the stock, which he views as a sign of underlying resilience. Karapetjanc states, "In my view, further growth is still possible if HIMS can reclaim $29.46 — the market offers multiple setups for patient bulls here."

Sholanke Dele, market strategist, adopts a cautious approach to Hims & Hers Health. He finds sentiment weak as the technical momentum is clearly negative and broader market confidence is absent. The ongoing high volatility only increases downside risk, especially with no supporting news flow to shift market mood. Dele remarks, "This is not a favorable environment for bullish positions — risk remains skewed to the downside in the short term."

Negative momentum persists as support and resistance levels constrain trading

Hims & Hers Health is trading below its 20-day, 50-day, and 200-day moving averages ($28.61, $29.88, and $27.86, respectively), indicating persistent seller pressure across all time frames. Immediate resistance is near $27.71 and support sits at $25.4, while the long-term bullish structure from the 50-day versus 200-day alignment provides only trend confirmation. Daily momentum remains negative, as highlighted by the MACD at -0.34 (Strong Sell) and a neutral ADX. The RSI at 47.42 (Sell), Stochastic RSI at 36.04 (Strong Sell), and CCI at 40.72 (Neutral) suggest a mix of downside risk and market indecision, with no clear oversold signal. Bull/Bear Power is positive at 2.27, showing buyers still dominate intraday, but this is outweighed by an overbought reading and the fading of a recent upside gap. Intraday volatility is high at 8.59%, and momentum indicators broadly confirm the prevailing downward tone.

Earlier, analysts noted that Hims & Hers Health faced heightened regulatory and legal risks, contributing to a generally negative outlook for the stock. The current analysis reinforces this bearish view as persistent technical weakness and sustained selling pressure suggest that a decisive move below $25.40 would pose a material downside risk in the near term.

Source of Data: HIMS Price Analysis by TU

The analysis is based on a proprietary model combining technical, on-chain, and expert data. Not investment advice. See methodology

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.